{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:17Z","timestamp":1790380817017,"version":"4.1.0"},"reference-count":96,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are recognized as a unique population with specific characteristics and needs. In adolescents age 15 to 20 years, the use of fully pediatric protocols is supported by many comparative studies of pediatric and adult cooperative groups. In young adults, growing evidence suggests that pediatric-inspired or even fully pediatric approaches may also dramatically improve outcomes, leading to long-term survival rates of almost 70%, despite diminishing indications of hematopoietic stem-cell transplantation. In the last decade, better knowledge of the ALL oncogenic landscape according to age distribution and minimal residual disease assessments has improved risk stratification. New targets have emerged, mostly in the heterogeneous B-other group, particularly in the Philadelphia-like ALL subgroup, which requires both in-depth molecular investigations and specific evaluations of targeted treatments. The remaining gap in the excellent results reported in children has many other contributing factors that should not be underestimated, including late or difficult access to care and\/or trials, increased acute toxicities, and poor adherence to treatment. Specific programs should be designed to take into account those factors and finally ameliorate survival and quality of life for AYAs with ALL.<\/jats:p>","DOI":"10.1182\/blood-2018-02-778530","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T14:05:31Z","timestamp":1528812331000},"page":"351-361","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?"],"prefix":"10.1182","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"first","affiliation":[{"name":"Adolescent and Young Adult Hematology Unit, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Paris, France;"},{"name":"Research Unit EA-3518, Paris Diderot University, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-1005","authenticated-orcid":false,"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[{"name":"Research Unit EA-3518, Paris Diderot University, Paris, France; and"},{"name":"Pediatric Hematology and Immunology Department, Robert Debr\u00e9 Hospital (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111812371782600_B1","unstructured":"US Department of Health and Human Services: Closing the gap: research and care imperatives for adolescents and young adults with cancer. https:\/\/www.cancer.gov\/types\/aya\/research\/ayao-august-2006.pdf. Accessed 15 January 2018."},{"issue":"7","key":"2019111812371782600_B2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111812371782600_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11684-015-0381-3","article-title":"Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia","volume":"9","author":"Pui","year":"2015","journal-title":"Front Med"},{"issue":"3","key":"2019111812371782600_B4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"2019111812371782600_B5","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2017-05-783852","article-title":"Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Lafage-Pochitaloff","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111812371782600_B6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111812371782600_B7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111812371782600_B8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.leu.2403000","article-title":"Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup","volume":"17","author":"Soulier","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2019111812371782600_B9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"2019111812371782600_B10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111812371782600_B11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3535","article-title":"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults [published correction appears in Nat Genet. 2016;48(12):1591","volume":"48","author":"Yasuda","year":"2016","journal-title":"Nat Genet"},{"key":"2019111812371782600_B12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMedicine"},{"issue":"12","key":"2019111812371782600_B13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"2019111812371782600_B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111812371782600_B15","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111812371782600_B16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111812371782600_B17","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2019111812371782600_B18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2019111812371782600_B19","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111812371782600_B20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"2019111812371782600_B21","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111812371782600_B22","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2019111812371782600_B23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3324\/haematol.2016.151035","article-title":"ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype","volume":"102","author":"Hirabayashi","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019111812371782600_B24","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/pbc.26116","article-title":"Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B\/ZNF384 gene fusion","volume":"63","author":"Shago","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"28","key":"2019111812371782600_B25","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2016.66.5547","article-title":"MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents","volume":"34","author":"Suzuki","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111812371782600_B26","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"2019111812371782600_B27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"13","key":"2019111812371782600_B28","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2003-11-3944","article-title":"Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy","volume":"104","author":"Asnafi","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111812371782600_B29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3324\/haematol.2013.086082","article-title":"The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest","volume":"98","author":"Ben Abdelali","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2019111812371782600_B30","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111812371782600_B31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111812371782600_B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) study AALL0434 [abstract]","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111812371782600_B33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"issue":"5694","key":"2019111812371782600_B34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"issue":"8","key":"2019111812371782600_B35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"O\u2019Neil","year":"2007","journal-title":"J Exp Med"},{"issue":"17","key":"2019111812371782600_B36","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","article-title":"NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study","volume":"113","author":"Asnafi","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111812371782600_B37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2005-12-4956","article-title":"Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia","volume":"108","author":"Breit","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111812371782600_B38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","article-title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","volume":"131","author":"Petit","year":"2018","journal-title":"Blood"},{"issue":"34","key":"2019111812371782600_B39","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111812371782600_B40","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111812371782600_B41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM199310283291810","article-title":"Acute lymphoblastic leukemia\u2014progress in children, less in adults","volume":"329","author":"Hoelzer","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111812371782600_B42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111812371782600_B43","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V104.11.1954.1954","article-title":"Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols [abstract]","volume":"104","author":"Testi","year":"2004","journal-title":"Blood."},{"issue":"12","key":"2019111812371782600_B44","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"2019111812371782600_B45","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.22189","article-title":"Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol","volume":"107","author":"Hallb\u00f6\u00f6k","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"2019111812371782600_B46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2019111812371782600_B47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111812371782600_B48","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1200\/JCO.2008.20.8959","article-title":"Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children\u2019s oncology group","volume":"27","author":"Nachman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111812371782600_B49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111812371782600_B50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111812371782600_B51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111812371782600_B52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111812371782600_B53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111812371782600_B54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.839.839","article-title":"Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol: results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group for Adult ALL (GMALL) [abstract]","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111812371782600_B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.762.762","article-title":"The upper age limit for a pediatric-inspired therapy in younger adults with Ph-negative acute lymphoblastic leukemia (ALL)? Analysis of the Graall-2005 study [abstract]","volume":"128","author":"Huguet","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111812371782600_B56","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111812371782600_B57","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"issue":"21","key":"2019111812371782600_B58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403 [abstract]","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111812371782600_B59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111812371782600_B60","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111812371782600_B61","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/bmt.2008.58","article-title":"Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials","volume":"41","author":"Schrauder","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111812371782600_B62","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111812371782600_B63","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.552.552","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): results from the Group for Research on Adult ALL (GRAALL) [abstract]","volume":"122","author":"Dhedin","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111812371782600_B64","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009;27(15):2574]","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111812371782600_B65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbmt.2012.08.020","article-title":"Survival differences between adolescents\/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation","volume":"19","author":"Burke","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111812371782600_B66","first-page":"829","article-title":"Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia","volume":"20","author":"Wood","year":"2014"},{"issue":"18","key":"2019111812371782600_B67","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"2019111812371782600_B68","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2019111812371782600_B69","article-title":"A treatment protocol with imatinib and intensive chemotherapy for pediatric Philadelphia positive acute lymphoblastic leukemia patients: a single-arm, intergroup study (EsPhALL 2010-2014) [abstract]","volume":"130","author":"Biondi","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111812371782600_B70","article-title":"CA180-372: an international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) [abstract]","volume":"130","author":"Hunger","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019111812371782600_B71","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"issue":"25","key":"2019111812371782600_B72","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111812371782600_B73","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111812371782600_B74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"23","key":"2019111812371782600_B75","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"2019111812371782600_B76","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111812371782600_B77","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"36","key":"2019111812371782600_B78","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111812371782600_B79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111812371782600_B80","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111812371782600_B81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111812371782600_B82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111812371782600_B83","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111812371782600_B84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/jayao.2015.0014","article-title":"Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase","volume":"4","author":"Boissel","year":"2015","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"11","key":"2019111812371782600_B85","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2019111812371782600_B86","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"Mattano","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111812371782600_B87","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111812371782600_B88","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.blre.2017.09.005","article-title":"Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults","volume":"32","author":"Friend","year":"2018","journal-title":"Blood Rev"},{"issue":"17","key":"2019111812371782600_B89","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2019111812371782600_B90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/1054-139X(94)90609-2","article-title":"Mania or panic associated with dexamethasone chemotherapy in adolescents","volume":"15","author":"Watanabe","year":"1994","journal-title":"J Adolesc Health"},{"issue":"8","key":"2019111812371782600_B91","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S1470-2045(14)70113-5","article-title":"Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials","volume":"15","author":"Fern","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111812371782600_B92","doi-asserted-by":"crossref","first-page":"e017052","DOI":"10.1136\/bmjopen-2017-017052","article-title":"Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England","volume":"7","author":"Hough","year":"2017","journal-title":"BMJ Open"},{"issue":"23","key":"2019111812371782600_B93","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMc1412123","article-title":"Ph-like acute lymphoblastic leukemia in older adults","volume":"371","author":"Herold","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111812371782600_B94","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/leu.2011.141","article-title":"Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40","volume":"25","author":"Rijneveld","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"2019111812371782600_B95","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3561.3561","article-title":"Dose-intensity impacts on survival of adolescents and young adults with acute lymphoblastic leukemia treated in adult departments by a pediatric protocol (FRALLE 2000BT) [abstract]","volume":"120","author":"Cluzeau","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111812371782600_B96","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-014-0210-9","article-title":"Pediatric-like therapy for adults with ALL","volume":"9","author":"Dombret","year":"2014","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/4\/351\/1407152\/blood778530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/4\/351\/1407152\/blood778530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:48:33Z","timestamp":1574081313000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/4\/351\/103892\/Acute-lymphoblastic-leukemia-in-adolescent-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-02-778530","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}